Month: October 2010

Healthcare

Pfizer to acquire King Pharmaceuticals for $3.6 billion.

Expert comment from Datamonitor principal analyst Simon King: “The King acquisition represents a small but integral part of a broader diversification strategy that continues to be implemented by Pfizer. This strategy has to date encompassed the multi-billion dollar acquisition of Wyeth but also various in-licensing agreements and a concerted movement into the generics market as…

15 Oct 2010, by Informa Insights

Healthcare

The case for constant innovation in Australian biotech

Melbourne – 12th October 2010 – The sales contribution from internally developed products is expected to decline from $284 billion in 2009 to $274 billion in 2014, by which time the majority of sales will be derived from externally sourced products. Pharma’s continued need to restock pipelines in order to secure future growth—in the face…

12 Oct 2010, by Informa Insights

Planning & Design

Transport & Logistics

Written interview with the CEO of NSW Business Chamber

We had the opportunity to get an interview with Stephen Cartwright, CEO, NSW Business Chamber, who is nice enough to give us a few minutes of his busy day to fill in some blanks for us! Building and maintaining transport infrastructure is of pivotal importance for the future prosperity of NSW. We had the chance…

11 Oct 2010, by Informa Insights

Healthcare

Asia-Pacific products are in later stages of development compared to other markets

Melbourne – 11th October 2010 – Asia-Pacific products are in later stages of development compared to other markets, but still comprise only 15% of global products in development according to MedTRACK, a market leading database of private and public biomedical companies. The volume of products in development in the Asia-Pacific region still lags behind North…

11 Oct 2010, by Informa Insights

Healthcare

Implications of Nivestim’s approval on the Australian biosimilars market

Melbourne – 6th October 2010 – Biosimilars in Australia: Nivestim approval opens up local filgrastim biosimilars market. Lisette Oversteegen, Lead Analyst, comments: “Although the recent approval of biosimilar filgrastim is a positive development for the Australian industry, the proposed biosimilars pricing regulations may slow uptake”. Compared with Europe, where several biosimilar products of three different…

6 Oct 2010, by Informa Insights

Healthcare

The Australian reimbursement committee is set to consider Novo Nordisk’s type 2 diabetes treatment

Melbourne – 5th October 2010 - Novo Nordisk: swift approval of Victoza for reimbursement is vital to the drug's success. Lisette Oversteegen, Lead Analyst, comments: “For a prescription drug to be commercially successful in Australia, being included on the country's government reimbursement list, the Pharmaceutical Benefits Scheme (PBS) is essential”. In its November meeting, the…

5 Oct 2010, by Informa Insights